Close Menu

NEW YORK (GenomeWeb) – Barclays has initiated coverage of Genomic Health, Quidel, and Cepheid while it upgraded Hologic's stock to Equal Weight.

In a research note, analyst Jack Meehan rated Genomic Health Underweight with a price target of $25 per share. "[O]pportunities for profitability are further out," he said, noting that he prefers other companies offering "more robust and better validated tests" for prostate cancer prognosis.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News examines how science in the UK may fare as Boris Johnson, the next prime minister, pursues Brexit.

CNN reports that Immigration and Customs Enforcement in the US has expanded its DNA testing to seven sites along the southern border.

In PNAS this week: role for exosomes in neuronal circuit development, tuberculosis pathogen enzymes, and more.

Undoing Obamacare protections could affect people's willingness to undergo genetic testing, Sarah Lawrence College's Laura Hercher and the University of Iowa College of Law's Anya Prince write at BuzzFeed News.